Differential Micro RNA Expression in PBMC from Multiple Sclerosis Patients by Otaegui, David et al.
Differential Micro RNA Expression in PBMC from Multiple
Sclerosis Patients
David Otaegui1*, Sergio E. Baranzini2, Ruben Arman˜anzas3, Borja Calvo3, Maider Mun˜oz-Culla1, Puya
Khankhanian2, In˜aki Inza3, Jose A. Lozano3, Tamara Castillo-Trivin˜o1,4, Ana Asensio1,4, Javier
Olaskoaga1,4, Adolfo Lo´pez de Munain1,4
1Multiple Sclerosis Unit, Biodonostia Institute, San Sebastia´n, Spain, 2Neurology Department, University of California San Francisco, San Francisco, California, United
States of America, 3 Intelligent Systems Group, Computer Science Faculty, University of the Basque Country, San Sebastia´n, Spain, 4Neurology Department, Hospital
Donostia, San Sebastia´n, Spain
Abstract
Differences in gene expression patterns have been documented not only in Multiple Sclerosis patients versus healthy
controls but also in the relapse of the disease. Recently a new gene expression modulator has been identified: the microRNA
or miRNA. The aim of this work is to analyze the possible role of miRNAs in multiple sclerosis, focusing on the relapse stage.
We have analyzed the expression patterns of 364 miRNAs in PBMC obtained from multiple sclerosis patients in relapse
status, in remission status and healthy controls. The expression patterns of the miRNAs with significantly different
expression were validated in an independent set of samples. In order to determine the effect of the miRNAs, the expression
of some predicted target genes of these were studied by qPCR. Gene interaction networks were constructed in order to
obtain a co-expression and multivariate view of the experimental data. The data analysis and later validation reveal that two
miRNAs (hsa-miR-18b and hsa-miR-599) may be relevant at the time of relapse and that another miRNA (hsa-miR-96) may be
involved in remission. The genes targeted by hsa-miR-96 are involved in immunological pathways as Interleukin signaling
and in other pathways as wnt signaling. This work highlights the importance of miRNA expression in the molecular
mechanisms implicated in the disease. Moreover, the proposed involvement of these small molecules in multiple sclerosis
opens up a new therapeutic approach to explore and highlight some candidate biomarker targets in MS.
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Introduction
Multiple sclerosis (MS) is a demyelinating disease of the central
nervous system (CNS). It begins most commonly during late
adolescence, young adulthood, or mid-life, and it is one of the most
incapacitating diseases in this age range.
MS causes attacks of neurological dysfunction (loss of vision,
difficulty in walking or moving a limb, vertigo, loss of sensation) or
progressive dysfunction in these same areas. These ‘‘attacks’’, also
known as relapses, typically last for a few days, and resolve
spontaneously. However, patients may not always completely recover
from an attack and are sometimes left with a disability. Althoughmost
patients experience attacks with little or no progressive disability,
called recurrent remittent (RR) forms, approximately 10–15% have
progressive symptoms from onset, called primary progressive forms.
Furthermore, more than 80% of patients that debut with RR will
ultimately develop progressive symptoms after a prolonged period of
exacerbations, usually after 10–20 years.
Etiologically, MS is a complex disease in which both genetic and
environmental factors play a role. The genetics of MS are also
complex without a clear inheritance pattern. The most relevant
candidate genomic region is the HLA system [1–3], although several
other genes are currently being described as important risk factors
involved in MS, as for example IL2RA [4] or IL7R genes [5].
Gene expression profiling has been a useful tool to provide
information about the molecular pathways involved in MS
pathogenesis [6–8]. Several new studies have identified different
expression patterns between relapses and remission [9,10]
suggesting that this clinical distinction of two states of the disease
also has a molecular correlation.
Small non-coding RNA molecules (microRNA or miRNA) are a
gene expression and protein synthesis modulating mechanism that
has been recently identified in several species ranking from worms
to humans. These miRNA are single-stranded RNA molecules of
about 20–25 nucleotides (nt) encoded by nuclear genes (70–150 nt)
and highly conserved among species. These genes are not
translated into proteins but are processed from primary transcripts
(called pri-miRNA) to short stem-loop structures called pre-
miRNA and finally to functional miRNA. The expression pattern
of miRNA varies over time and between tissues. These mature
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miRNA molecules are partially complementary to one or more
mRNA sequences and they function through sequence-specific
down-regulation of their target mRNA via mRNA degradation or
inhibition of translation [11]. Initial computational analysis
suggested there were more than 500 validated human miRNA
[12,13], although in the public database (mirbase) around 700
were proposed in October 2008.
It has been predicted that miRNAs may regulate around 30% of
all cellular mRNA suggesting that these molecules play a critical
role in virtually all cellular functions [14].
Although dysregulation of miRNA expression has been
characterized mostly in cancer, it has recently been studied in
many other diseases. Specifically, miRNAs have been proposed as
a regulator of immune cell development [15], playing a role in the
inflammatory response [16], and as a key player in the
pathogenesis of neurodegenerative diseases [17].
We are reporting our study of the expression of 364 miRNA in
samples from MS patients during a relapse and during remission,
along with healthy controls, with the aim of understanding the
regulatory mechanisms of these stages.
Materials and Methods
Recruitment of individuals
All patients were recruited in the Neurology Department of
Hospital Donostia, located in the region of Gipuzkoa (Basque
Country, Spain). The study was approved by the local institutional
review board and all the samples were obtained with the written
informed consent of the subjects. The patients were diagnosed as
having MS according to the Mc Donald Criteria [18,19].
In a first group (Group A), 21 blood samples were obtained: 9
from patients in remission, 4 from patients during a relapse before
the administration of steroids and 8 from healthy volunteers. Total
RNA, including miRNA, was extracted from these samples to
carry out the study. Demographic data of the individuals studied
can be found in Table S1.
Samples were collected from two other non-related groups to
validate independently some of the results obtained. Figure 1
summarizes the groups and the methods used:
– Group B: mRNA was obtained from 27 patients (14 during
remission and 13 during relapse) and from 15 controls.
– Group C: miRNA was extracted from 7 patients (4 during
relapse and 3 during remission) and from 7 healthy controls.
Blood extraction was always performed in the early morning and
RNA extraction was carried out nomore than 2 hours after the blood
was collected and during this time was kept at 4uC. In all the cases,
10 ml of blood were collected in EDTA tubes by venipuncture.
RNA extraction, reverse transcription (RT) and
quantitative PCR (qPCR)
In groups A and C, total RNA was extracted from blood using
the Ambion Leucolock kit (AM1923) working with the alternative
protocol so as to keep the small RNA fraction.
The RNA obtained was quantified in triplicate using a
NanoDrop spectrophotometer (NanoDrop Technologies, USA).
A common bias in the interpretation of the miRNA profiles from
whole blood may be introduced by the high concentration of
miRNA from erythrocytes [20]. In our study we avoided such a
bias by isolating PBMC in a filter prior to RNA purification (see
Ambion Leucolock kit protocol).
cDNA was synthesized from total RNA using a Multiplex RT
for Taqman array kit (Applied Biosystems, Foster City, CA).
Figure 1. Workflow of the different approaches used in the work. The samples groups are specified and the selected genes are listed.
doi:10.1371/journal.pone.0006309.g001
miRNA in MS
PLoS ONE | www.plosone.org 2 July 2009 | Volume 4 | Issue 7 | e6309
Briefly, this kit consists of 8 pre-defined RT primer pools
containing up to 48 RT primers each. Each of these 8 pools
contains the same endogenous controls (RNU48). This technology
has been developed to detect only full length mature miRNA but
not their precursors or their partially-degraded products.
We performed qPCR using the TaqmanH Low Density Array
(TLDA) Human MicroRNA Panel v1.0 from Applied Biosystems
(see table S2 for a map of this array). This TLDA included 365
miRNA assays plus two selected endogenous controls. The qPCR
was performed using an Applied Biosystems 7900 Sequence
Detection System. Ct values were determined using the automatic
threshold in RQ manager v1.1 analysis software.
Two normalization steps were used: the first normalization
consisted in loading the same quantity of template RNA in each
well and the second in normalizing the data against an
endogenous gene. This endogenous control (RNU48) was chosen
for this study as the least variable of all endogenous genes included
in the TLDA assays. Consequently, data was normalized to
RNU48, using the values of each of the 8 pools, i.e. each gene pool
was normalized against the endogenous gene that was converted
to cDNA in the same pool, to avoid introducing bias in the results.
Relative quantification of miRNA expression was calculated
with the 2-ddCT method (Applied Biosystems User Bulletin Nu 2
(P/N 4303859)). Quality of the data and quantification was
computed using Real-Time Statminer software (www.integro-
mics.com). This software performs a moderate t-test between the
groups (relapse, remitting and control) and corrects them using the
Benjamini-Hochberg algorithm [21] with the False Discovery
Rate (FDR) set at a value of 5%.
Samples from group B belong to an ongoing cohort collected by
our group. These samples were extracted using the Versagene TM
Kit (Gentra, Minneapolis, USA). This method entails the loss of
the small molecules of RNA, i.e. miRNA.
Statistical data analysis
A non-parametric analysis that complements the classical t-test
analysis was performed trying to reveal alternative results over the
low number of available samples. We compared the expression
patterns of our three groups by pairs: relapse vs remitting, relapse
vs control and remitting vs control. To accomplish this task, a non-
parametric ranking method called Symmetrical Uncertainty (SU)
sorts all the miRNA according to their statistical relevance over
each of the three comparisons using the following coefficient,
SU Y ,Cð Þ~ 2 H Yð Þð Þ{H Y jCð Þ)
H Yð ÞzH Cð Þ
where Y is the predictive variable (in our case, each miRNA), C is
the class label to be predicted (depending on the comparison
carried out, it takes two of the following three values: remitting,
relapse and control), H(Y ) is the entropy of Y and H(Y|C ) is the
conditional entropy of Y given C [22].
The SU ranking is based on the mutual information between
each miRNA expression level and the phenotype label. Being a
univariate coefficient, it measures the uncertainty reduction of the
class variable C when the expression value of a miRNA (denoted as
Y in the above formulation) is known. As the SU metric only takes
discrete/categorical variables, the DCT expression of each
miRNA was first discretized into three intervals by using an equal
width discretization method.
In order to get a multivariate view of the experimental data, we
built co-expression networks to investigate the possible regulations
within two out of our three comparisons (relapse vs remitting and
remitting vs control). For this purpose we borrowed a technique for
building gene interaction networks [23] and applied it to our DCT
expression data. We used an algorithm that makes use of three
main components to find reliable dependences from data: a
bootstrap re-sampling algorithm, a supervised Bayesian network
classifier and a dimensionality reduction technique. The algo-
rithm’s construction scheme is focused on finding highly reliable
dependences from raw data. The bootstrap step re-samples the
original data B times, obtaining B similar datasets. For each
sampled dataset a dimensionality reduction step is made using the
correlation-based filter selection approach (CFS) [24]. The CFS
returns sets of relevant features that show a high degree of
correlation with the class label while the redundancy degree
among them is kept as low as possible. Each sampled dataset is
projected to contain only the selected features and afterwards a k-
dependence Bayesian [25] network classifier is induced from that
data. All the identified probabilistic dependencies between pairs of
nodes in the B final classifiers are stored. Note that the
dependencies with respect to the supervised variable are not taken
into account.
The algorithm’s output is a hierarchy of probabilistic depen-
dencies found during the whole process. When a cut-off threshold
T is set, it is possible to retrieve a graphical structure in which only
those probabilistic conditional dependencies that have been
configured at least T times are displayed. Each arc in the final
structure is associated with a robustness value which reflects the
number of times the arc is configured in the different bootstrap re-
samplings.
We perform a total of 10,000 re-samplings with their
corresponding CFS and k-DB data mining techniques. The value
of k in k-DB was set to four, keeping to the value suggested in the
original work.
Sequence of the miRNA genes
The miRNA genes were amplified by PCR (primers sequences
available on request) and the PCR product was sequenced in an
ABI3130 automatic sequencer (Applied Biosystems) using Bigdye
v3.1. The used primers were designed based on the mirbase
[13,26,27] sequence information and using the Generunner
software (www.generunner.com). Group A samples (n = 21) were
analyzed as well as 40 healthy controls. These healthy controls
came from a cohort recruited in our group to test sequencing
results, all the samples comes from healthy volunteer donors
without neurological symptoms.
Validation of the target genes
We studied an independent set of 42 samples (group B). The
expression of predicted targets of the identified miRNAs was
analyzed by qPCR using SYBRgreen as fluorescent and pre-
designed primers from geneglobe (www.geneglobe.com). The
assay codes can be found in Table 1. The data were analyzed
using the same software and the same methodology described
above, using as the endogenous gene GAPDH.
Individual validation of the miRNA expression
Validation of the expression of the selected miRNA genes was
performed in an independent set of 14 samples (Group C). The
qPCR was performed in a 7900 sequence detection system using
pre-designed Taqman probes (Applied Biosystems).
Results
We used qPCR to study the expression of 364 miRNAs in
samples from 4 MS patients during a relapse and from 9 patients
during remission. We also analyzed 8 healthy controls.
miRNA in MS
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On average, 45% of the miRNAs analyzed were expressed in
any given sample. Differences in the expression of the miRNAs
was tested between the different groups; relapse vs remitting,
remitting vs controls, MS vs controls and relapse versus controls.
Although several miRNAs reached nominal significance in the
t-test, only three remained significant after correction for multiple
testing (with an FDR threshold of 5%) in all three pairwise
comparison sets.
The transcript hsa-miR-18b showed increasing expression in
the relapsing group when compared to controls (RQ: 52.1). The
transcripts hsa-miR-493 and hsa-miR-599 showed reliable
expression in the relapsing group whereas they were not detected
in controls. These two miRNA were also expressed in the
remission group but did not reach any statistical significance in the
comparisons. (See fig. 2, DDCT and p values of all the
comparisons are provided in table S3)
In order to complement the information of the classical
statistical analysis, we calculated the symmetrical uncertainty
(SU) correlation degree of each miRNA with respect to the class
phenotype, providing a ranked list of all miRNAs. The top ten
miRNA emerging from these rankings are shown in Table 1.
Rankings were made for three different comparisons; relapse
versus remitting, remitting versus controls and relapse versus controls.
Highlighted in red are the significant miRNA found in the previous
analysis (Complete data analysis could be found as table S4).
A coexpression network analysis was performed to obtain
information about the relationships between the different miRNA
(as explained in material and methods). Two interaction networks
were built according to the studied groups;
– relapse versus remitting, in order to obtain information
about the relapse phenomena in the patients
– remission versus controls, in order to obtain information
about the Remission stage. (Fig. 3A-B)
From these analyses of the expression data (t-test, SU and
coexpression networks), we selected 7 miRNA in which we
performed further analysis (see Table 2);
– We chose three miRNA, hsa-miR-18b, hsa-miR-493 and
hsa-miR-599, because they reach the significance level in the
corrected t-test used to compare relapse status with control
samples.
– We selected four miRNA, hsa-miR-148a, hsa-miR-184,
hsa-miR-193a and hsa-miR-96, coming from the network
analysis that differentiates between remission and control
groups. From this network we chose the miRNA with the
higher degree (hsa-miR-96), the two with arcs showing the
highest robustness values (hsa-miR184 with 1557 robustness
scores and hsa-miR-193a with 1358 robustness scores) and the
other parent of hsa-miR96, the hsa-miR-148a.
Validation of the miRNA expression
To validate these results we studied the following three miRNA:
miR-18b, miR-96 and miR-599, in an independent set of samples
(group C). We choose two miRNA coming from the T-test
analysis, and another one coming from the coexpression network.
miR-18b and miR-599 were up-regulated four and five times
more in the relapse group than in the controls. For miR-96 we
obtained no differences in the expression between the groups.
Sequencing of the miRNA genes
To discard a DNA conformation effect in the expression of the
miRNA, we sequence three genes (hsa-miR-18b, hsa-miR-493 and
hsa-miR-96) in the 21 studied samples and in an additional group
of 40 samples. We choose randomly two genes characteristic of the
relapse group (hsa-miR-18b and hsa-miR-493) and another from
the remitting group (hsa-miR-96). No polymorphisms had been
found in the sequenced samples.
miRNA targets
In order to provide a biological interpretation of our findings,
we searched the predicted targets of each relevant miRNA in three
different databases; mirbase targets v5, Targetsan v4.2 [28–
30] and Pictar [31]. Table 3 lists the number of predicted targets
for these miRNA according to each database (two searches with
different confidence thresholds were performed in mirbase). A
complete list of the targets could be found in table S5)
Theoretically, these miRNA should inhibit the expression of a
certain number of target genes. The databases offer predicted
information about the targets, but there are few experimental
results to support it. In our analysis we took a conservative
approach, taking as target genes only the common results from the
three different prediction algorithms (in the mirbase case we
selected the p,0.005 column).
To validate these results, we tested the expression of four
selected targets of the miRNA more representative of each group
in blood from an independent sample set (GroupB), but we saw no
statistical differences in these expression pattern. Table S6 presents
the miRNA that target these genes and the group in which it is
expected to be down-regulated.
Since miRNA are highly conserved across species [32,33], we
used the murine EAE model to validate our findings. To this end,
we mined a large multi-tissue, longitudinal gene expression
profiling dataset in mouse EAE Lymph Node [9] and Spinal cord
[34], focusing on targets of those miRNA differentially expressed
in our cohort of MS patients. Briefly, EAE was induced in 84
female NOD mice by s.c. injection into their lower flanks with
MOG35–55 peptide emulsified in CFA containing 4 mg/ml
Mycobacterium tuberculosis (Difco). Immediately thereafter and 48 h
later, an i.v. injection of 350 ng of Bordetella pertussis toxin was
administered to the animals. The control group consisted of
another 26 female mice treated with the same protocol except
MOG peptide. Samples were extracted at different time points
Table 1. Top 10 genes from the SU analysis for each of the
three comparisons.
Relevance as Symmetrical Uncertainty
Relap vs. Rem Rem vs. CON Relap vs. CON
gene SU gene SU gene SU
1 hsa-miR-542-5p 0.5277 has-miR-96 0.4832 hsa-miR-599 0.8651
2 hsa-miR-376a 0.4921 hsa-miR-30a-5p 0.2989 hsa-miR-18b 0.6416
3 hsa-miR-18b 0.4048 hsa-miR-30e-5p 0.2959 hsa-miR-423 0.6367
4 hsa-miR-34c 0.4039 hsa-miR-599 0.2959 hsa-miR-125b 0.5738
5 hsa-miR-489 0.4039 hsa-miR-193a 0.2959 hsa-miR-383 0.5392
6 hsa-miR-554 0.4039 hsa-miR-337 0.2959 hsa-miR-509 0.5392
7 hsa-miR-600 0.4039 hsa-miR-449b 0.2591 hsa-miR-30e-5p 0.5392
8 hsa-miR-652 0.4039 hsa-miR-184 0.2477 hsa-miR-487b 0.5167
9 hsa-miR-214 0.3863 hsa-miR-328 0.2283 hsa-miR-222 0.4970
10hsa-miR-328 0.3729 hsa-miR-146b 0.2238 hsa-miR-127 0.4965
Genes in red were also significant in the corrected t-test.
doi:10.1371/journal.pone.0006309.t001
miRNA in MS
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obtaining a longitudinal model of the disease. In each extraction
RNA from Spinal cord and lymph node were obtained. The
animals were clinically scored every days during the experiment
and were classified in four groups: without clinical symptoms,
Starting with the symptoms, in the peak of the disease and
recovering from the peak.
In order to check whether our target selected genes were really
related with the disease, we created a group of 11 randomly
selected miRNA from those that were not differentially expressed
in our first analysis.
We compared the expression of the target genes (see table 3) for
the two groups (7 miRNA from our data and 11 miRNA randomly
choose) at the peak of the disease and at the recovering stages
between the control and the EAE group.
The target genes were classified the target genes in four groups:
not found in the dataset, up-regulated, down-regulated and
equally-expressed.
The results are summarized as percentages in Fig. 4. A chi-square
analysis was performed between the groups. The figure shows the
results of the analysis for the selected genes (in blue) and for the
Figure 2. The charts show the log10 expression relative quantification values of 365 miRNA genes between Relapse (target) and
control (calibrator) groups. A: this chart shows the values from the 361 genes that not passed the False discovery rate threshold (p = 0.05). B:
Shows the values from the three genes that pass the false discovery rate threshold. Yellow: Calibrator not detected. Black: No detection. Red: Target
not detected. Blue both (target and calibrator) detected.
doi:10.1371/journal.pone.0006309.g002
miRNA in MS
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randomly selected group (in pink). The analyzed target-genes were
differentially distributed (p,0.001) between experimental and
random group in the up-regulated and down-regulated class.
A pathway analysis was conducted in Panther [35] database for
all miRNA (experimental and random). A resume of the methods
used for panther are available in Supplementary data as Text S1.
Out of the seven miRNA targets (miR-18b, miR-599, miR-493,
miR-184, miR-148a, mir-96 and miR-193a) only targets of miR-
96 appeared significantly enriched in 8 pathways (see table 4 for
miR96 results. All the data could be found at table S7).
Discussion
We identified three miRNA (hsa-mir-18b, hsa-mir-493 and hsa-
mir-599) showing differential expression between MS patients
experiencing a relapse and controls. Classic parametric tests did not
detect differentially expressed miRNA between samples from
patients in remission vs controls, from MS vs controls or from
relapse vs remission. However, a network-based approach identified
4 miRNA (hsa-mir-96, hsa-mir-148a, hsa-mir-184 and hsa-mir-193)
that could be interesting candidates related with the remission stage.
According to the miRNA function, we hypothesized that if a
given miRNA was over-expressed in a particular group of samples,
the predicted targets of this miRNA should be down-regulated. To
check this hypothesis, although this is an indirect approach, we
analyze the expression data coming from a longitudinal dataset in
mouse EAE model. Interestingly, in this model the target genes of
all 7 differentially expressed miRNA appeared significantly down-
regulated more times in the targets selected by our experiment
than in a random target list. However, we observed a similar effect
for the up-regulated genes. These genes may be being downreg-
ulated in a translational form and the upregulation of the mRNA
could be a retroactive mechanism to valance that.
A biological interpretation of miRNA function in MS is
complicated by the fact that most of the miRNA targets are
predicted from bioinformatics analysis and are not yet validated in
biological studies. To enhance our confidence, we only worked
with consensus targets from the three public miRNA databases.
Patients in relapse status
A t-test identified three differentially expressed genes between
relapse and control samples. We would expect the same
differences between relapse and remitting groups, however mir-
18b and mir-599, but not mir-493, were up-regulated during a
relapse, showing a trend that did not reach significance after FDR
correction. Moreover in the relapse versus remitting network, two
of these genes, miR-18b and miR-599 appear to be correlated with
a direct probabilistic relationship (with a 733 robustness score).
The expression of these two genes have been validated in an
independent set of samples. Taken all together, these results
suggest that miR-18b and miR-599 are related in some way to the
Figure 3. Gene interaction networks from the qPCR data. A: Relapse versus remission status. B: Remission versus control status. Numbers
represents robustness score (see material and methods for details). The genes that had at least one parent had been noted with a shaded blue oval.
doi:10.1371/journal.pone.0006309.g003
Table 2. Selected microRNA based in qPCR experimental
data.
Relapse Remitting Selected by Gene ID chromosome
hsa-mir-18b FDR corrected T-test 547033 Xq26.2
hsa-miR-493 574450 14q32.31
hsa-mir-599 693184 8q22.2
hsa-miR-96 co-expression
networks
407053 7q32.2
hsa-miR-184 406960 15q25.1
hsa-miR-148a 406940 7p15.2
hsa-miR-193a 406968 17q11.2
doi:10.1371/journal.pone.0006309.t002
miRNA in MS
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Table 3. Predicted number of genes targets for each miRNA in three databases.
mirbase Pictar Targetscan Common
p,0.05 p,0.005
18 775 327 151 149 14
599 783 185 X 173 11 Relapse vs Control
493 866 244 X 496 3
96 909 361 698 592 57
184 819 289 22 17 3 Non relapse vs Control
193 918 353 429 434 46
819 362 134 208 14
The column labeled as ‘‘common’’ represents the common predicted targets in the three databases. The Gene symbol of these target genes could be found in
supplementary methods, table 3.
doi:10.1371/journal.pone.0006309.t003
Figure 4. Percentage of the targets founded in the EAE experiment. The founded targets were grouped in up-regulated, down-regulated
and equally regulated between the EAE group and the control. The data from the 7 selected miRNA are presented in blue and the data from the
randomly selected 11 miRNA in pink
doi:10.1371/journal.pone.0006309.g004
miRNA in MS
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mechanisms of the relapse. Their role remains unclear, but should
be related with the regulation of the proposed target genes.
In the analyses of the pathways in which the target genes of
these two miRNA are implicated, neither the target genes of each
miRNA individually nor the target genes in common between
both miRNA give significant results.
The study of the target genes in patients showed no clear
inhibition, as it might be expected, perhaps because regulation of
the miRNA is occurring at the translational level rather than at the
expression level.
These results support the idea that the expression of the miRNA
could be useful as a biomarker of the relapse status.
Patients in remitting status
The proposed network obtained in the comparison between
samples from patients in remission and control samples identified
four miRNAs likely to be implicated in the relapses (hsa-miR-148a,
hsa-miR-184, hsa-miR-193a and hsa-miR-96). The results suggest
that hsa-miR-96 could be an important candidate for further
studies. hsa-miR-96 is first in the SU ranking when remitting and
control groups are compared. Although the classic qPCR analysis of
the expression of this gene gave no significant differences, we note
that this gene is more highly expressed in remitting samples than in
controls, and less in relapse samples than in remitting. The data
from the SU analysis, the network relations and the trend in the
qPCR data suggests that has-miR-96 might be characteristic of the
remitting phase of the disease. In the validation with an independent
set the results of the qPCR data are the same: no differences
between the groups but a similar trend in the data.
A Gene Ontology analysis with the target-genes of miR-96 gave a
list of 8 categories that reached significant level. As could be
expected, within this list we found a classic immune-associated
pathways such as Interleukin signaling pathways. Two other pathways,
the Metabotropic glutamate receptor group I pathway and the Muscarinic
acetylcholine receptor 1 and 3 signaling pathway, related with Glutamate,
are also present. Glutamate has been widely related with
pathological mechanisms of the MS such as exocitotoxicity
[36,37]. Although these pathways have been more extensively
described in the CNS, they may well play a role in activated T-cells.
Another significant GO category pointed toward the Wnt
signaling pathway. Wnt has been proposed as an important player in
the development of effector T-cells and in the activation of the
regulatory T-cell [38].
These miRNA and these pathways could be good candidates in
further studies about biomarkers and to understand the etiology of
the MS
MS and miRNA
A relationship between miRNA expression and MS is not
unexpected as some of the functions attributed to the miRNA
include stress response, immunomodulation [39,40] and neuropro-
tection [17]. Moreover, bioinformatics-based predictions have
suggested that 30% of the human genes are regulated by miRNA
[41]. We therefore hypothesize that a sizeable proportion of the
mRNA differentially expressed between samples from patients during
a relapse and during remission could be regulated by miRNAs.
Our results support the role of miRNA expression patterns in
MS. The reliability of the data is sustained by the different
statistical approaches, by validation in an independent cohort of
samples and by the congruent results, both in the gene ontology
analysis and in the animal model analysis.
Although these studies should be replicated in a larger cohort of
samples, here we describe a list of miRNAs that could be good
candidates in future biomarker studies in MS and at least two
more with potential to be good markers to characterize the relapse
status.
Supporting Information
Table S1 Clinical description of the patients. Tev: Time of
evolution (years). EDSS: Expanded Disability Status Score. Te:
Time from the relapse onset and the blood extraction (in days)
Found at: doi:10.1371/journal.pone.0006309.s001 (0.03 MB
DOC)
Table S2 Taqman probes distribution in the Taqman Low
density array (www.appliedbiosystem.com)
Found at: doi:10.1371/journal.pone.0006309.s002 (0.05 MB
XLS)
Table S3 DCT data from the TLDA analysis. The data comes
from the different comparisons: MS (relapse and remitting) vs
Controls; Relapse (Relap) vs controls; remitting(Remitt) vs controls
and relapse vs remitting
Found at: doi:10.1371/journal.pone.0006309.s003 (0.32 MB
DOC)
Table S4 Complete data from the non-parametrical statistical
analysis
Found at: doi:10.1371/journal.pone.0006309.s004 (0.15 MB
XLS)
Table S5 Complete list of the miRNA predicted targets
Found at: doi:10.1371/journal.pone.0006309.s005 (0.05 MB
XLS)
Table 4. Pathway analysis of the hsa-miR-96 targets.
Pathway_hsa-miR-96 targets NCBI 96 expected ratio P-value
Muscarinic acetylcholine receptor 1 and 3 signaling pathway 62 5 0.14 35.7 5.39E-05
Alpha adrenergic receptor signaling pathway 29 3 0.06 50.0 6.88E-03
Unclassified 22436 39 50.29 0.8 1.01E-02
Endothelin signaling pathway 98 4 0.22 18.2 1.23E-02
Interleukin signaling pathway 194 5 0.43 11.6 1.29E-02
Wnt signaling pathway 348 6 0.78 7.7 2.18E-02
Histamine H1 receptor mediated signaling pathway 43 3 0.1 30.0 2.19E-02
Metabotropic glutamate receptor group I pathway 44 3 0.1 30.0 2.35E-02
Angiotensin II-stimulated signaling through G proteins and beta-arrestin 53 3 0.12 25.0 4.04E-02
doi:10.1371/journal.pone.0006309.t004
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Table S6 Target genes studied with their gene ID, the miRNA
that binds to the gene, the group in which these genes are expected
to be down-regulated and the Geneglobe Assay code.
Found at: doi:10.1371/journal.pone.0006309.s006 (0.03 MB
DOC)
Table S7 Data from the pathway analysis conducted by panther
with the predicted gene target lists from each miRNA. Two
different groups of miRNA were studied; coming from the
experiment and coming from the chance group
Found at: doi:10.1371/journal.pone.0006309.s007 (0.05 MB
DOC)
Text S1 Resume of the panther software methods
Found at: doi:10.1371/journal.pone.0006309.s008 (0.03 MB
DOC)
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